You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


AbbVie’s Venclexta granted full US approval in AML

The US Food and Drug Administration (FDA) has fully approved AbbVie’s Venclexta in acute myeloid leukaemia (AML).